FDA ponders future of NSAIDs: Pfizer reluctantly withdraws Bextra.
Young
Donna
D
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D002318:Cardiovascular Diseases / Q000139:chemically induced; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects*; D004345:Drug Industry / Q000331:legislation & jurisprudence*; D004335:Drug and Narcotic Control; D017408:Guidelines as Topic; D006801:Humans; D007555:Isoxazoles / Q000009:adverse effects*; D013449:Sulfonamides / Q000009:adverse effects*; D014481:United States; D014486:United States Food and Drug Administration; D000096926:Benzenesulfonamides
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D007555:Isoxazoles; D013449:Sulfonamides; C406224:valdecoxib; D000096926:Benzenesulfonamides